Tributary Capital Management will reduce its holding in Integra LifeSciences Holdings Co.

Tributary Capital Management LLC, a reputable investment management firm, recently lowered its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART). Tributary Capital Management LLC reduced his stake in Integra LifeSciences by 3.9% in the fourth quarter, according to the company’s latest disclosure to the Securities and Exchange Commission. The fund now owns 287,536 shares in life sciences companies after he sold 11,653 shares during the quarter.

Integra LifeSciences Holdings Corp. is a leading provider of regenerative tissue technology and neurological solutions aimed at reducing clinician uncertainty. The Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments offer a wide range of technologies and instruments used in neurosurgery, neurocritical care and otolaryngology.

Several equity analysts share their insights on the trajectory of Integra LifeSciences’ stock price. TheStreet recently upgraded Integra LifeSciences stock from a ‘c+’ rating to a ‘b-‘ rating in a research report. Meanwhile, StockNews.com rated him ‘Buy’ on Thursday, March 16, when he began covering Integra LifeSciences shares. Other analysts offer varying ratings from neutral to hold.

Despite these mixed opinions from well-known analyst firms, Bloomberg reports that Integra LifeSciences Holdings Co.’s current average consensus rating is Hold, with an average target price of $58.17 per share. It is said that

Tributary Capital Management LLC owned approximately 0.34% of Integra LifeSciences worth $16,122,000 at the end of the most recent quarter. It previously held equities, making up about 1.6% of the investment portfolio, making it the fund’s largest position, but has since declined by about 4%. Only time will tell if this was a wise decision by the investment manager.

Integra LifeSciences: Leading Potential for Regenerative Tissue Technologies and Neurological Solutions

Integra LifeSciences Holdings Corp is a leading provider of regenerative tissue technology and neurological solutions that minimize clinician uncertainty. His Codman Specialty Surgical (CSS) segment of the company includes techniques and instruments used in neurosurgery, neurocritical care and otolaryngology. Its Tissue Technology (TT) segment includes surgical implants made from living tissue such as tendons, ligaments and skin.

There has been some interesting recent activity in Integra LifeSciences stock among hedge funds and other institutional investors. Fifth Third Bancorp expanded his position in life sciences stocks by 40.8% in the fourth quarter after acquiring an additional 183 shares during the period. In the fourth quarter he increased his stake in Integra LifeSciences by 1.0% after the Louisiana State Employees Retirement System also purchased an additional 200 shares of his stock during the period. Similarly, the State of Michigan Retirement System increased his Integra LifeSciences stock position by 1.1% in the same quarter after purchasing an additional 200 shares.

Financial institutions are also eyeing the growth potential of Integra LifeSciences. Especially given his recent earnings report, which posted earnings per share (EPS) of $0.94 for the fourth quarter of 2020, beating analyst consensus expectations of $0.93. The company made $398 million in revenue for the quarter, compared to consensus expectations of $398.57 million.

Integra LifeSciences as a business appears to have positive prospects for future growth, but it’s worth noting that some insiders have sold part of their holdings in recent months. For example, EVP Michael J. Mcbreen said that in early March he sold more than 1,800 shares at an average of $54.29 per share, bringing the total deal value he exceeded $100,000.

Integra LifeSciences Holdings Co., with a current market capitalization of $4.68 billion and a net profit margin of 11.59% for fiscal 2020, analysts expect the company to post earnings per share (EPS) of 3.48 for the current fiscal year doing. Despite several uncertainties surrounding the future of the company and its stock, Integra LifeSciences is committed to continuing to develop innovative solutions for clinicians seeking to reduce risk during surgery and other medical procedures. It looks like you can.

Overall, it is clear that Integra LifeSciences’ position as a leader in regenerative tissue technology and neurological solutions has not been overlooked by investors and financial institutions. As such, those looking for solid medium- to long-term investment opportunities should keep an eye on the progress of this innovative Life Science company.